SEI Investments
MLTX icon

SEI Investments’s MoonLake Immunotherapeutics MLTX Stock Holding History

SEI Investments’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,662
Closed -$1.4M – 2874
2025
Q2 		$1.4M Buy
29,662
+2,274
+8% +$92.6K ﹤0.01% 1788
2025
Q1 		$1.07M Buy
27,388
+5,363
+24% +$231K ﹤0.01% 1878
2024
Q4 		$1.19M Buy
22,025
+1,202
+6% +$61.4K ﹤0.01% 1864
2024
Q3 		$1.05M Buy
+20,823
New +$976K ﹤0.01% 1931
2023
Q4 		– Sell
-31,790
Closed -$1.81M – 2657
2023
Q3 		$1.81M Buy
+31,790
New +$1.75M ﹤0.01% 1645

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SEI Investments's MLTX Position: Q3 2025 in Review

SEI Investments sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 29,662 shares — an estimated $1.4M sold.

SEI Investments first reported a position in MLTX in Q3 2023 and held it in 5 quarters. The position peaked at $1.81M in Q3 2023. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • SEI Investments reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • SEI Investments sold 29,662 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $1.4M.
  • SEI Investments first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 5 quarters.
  • SEI Investments's MoonLake Immunotherapeutics position peaked at $1.81M in Q3 2023.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on SEI Investments's 13F filing for Q3 2025, filed 13 Nov 2025.